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The late and fast developments in the ﬁeld of viral hepatitis were
highly expected in the 2014 AASLD Liver Meeting. Several com-
binations using direct acting antivirals (DAAs) showed high rates
of sustained virological response (95%). Importantly, high cure
rates were also demonstrated in patients with previous treat-
ment failures, decompensated cirrhosis and hepatitis C recur-
rence after transplantation, making it clear that the interferon
era is over (not so clear for ribavirin, which might still have a role
in difﬁcult-to-treat populations). Importantly, sustained viro-
logical response was associated with an improvement in liver
function (MELD and Child-Pugh scores) in patients with advanced
liver disease. In the ﬁeld of liver cirrhosis, there were relevant
data assessing the optimal empirical antibiotic therapy in
patients with spontaneous bacterial peritonitis and high risk of
resistant bacteria, as well as studies evaluating the role of terli-
pressin in type I hepatorenal syndrome and in septic shock.
Regarding hepatic encephalopathy, two randomized trials sug-
gest that the manipulation of the microbioma in patients with
cirrhosis may have a role in the management of this complica-
tion. Some novel data on NASH support the beneﬁcial effect of
bariatric surgery (after failure of lifestyle intervention) in morbid
obese patients with such diagnosis: clinical and histological
improvements after surgery were evident in most patients with
sufﬁcient follow-up. A few controlled studies focused on the
treatment of severe acute alcoholic hepatitis. Finally, several
studies on hepatocellular carcinoma (HCC) were presented,
covering topics such as ultrasound screening in cirrhosis, cryoab-
lation treatment of early HCC and the relevance of downstaging
in patients with HCC awaiting liver transplantation.
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by Elsevier B.V. Open access under CC BY-NC-ND license.Journal of Hepatology 20
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Despite the outstanding development of new compounds to treat
hepatitis C infection, there are still several unmet needs, includ-
ing: 1) data from real-life cohorts evaluating the new antiviral
combinations, 2) more efﬁcacious therapies for difﬁcult-to-treat
patients, such as, non-responders to a previous course of therapy
with a direct acting antiviral agent (DAA), genotype (G) 3-infect-
ed patients, decompensated cirrhotic patients and liver trans-
plant recipients, and 3) new antiviral combinations allowing
shorter treatment durations. In the last AASLD Liver Meeting,
several studies addressed these issues and brought new and
exciting information to the ﬁeld (Table 1).Real-life cohorts
When antiviral therapies are used in clinical practice rates of sus-
tained virological response (SVR) are usually lower as compared
to the results obtained in registration trials. This is explained,
in part, because difﬁcult-to-treat populations are typically not
included in these trials. In addition, side effects not observed in
trials may appear after drugs have been registered. Therefore,
results from these type of studies using new antiviral combina-
tions are relevant.
Data from two large real-life cohorts evaluating sofosbuvir
(SOF, a nucleotide NS5B inhibitor)-based therapies were present-
ed at the meeting. Dieterich et al. reported data from 955 indi-
viduals included in the TRIO network [1]. Patients received a
12-week regimen either with SOF + pegylated interferon
(PegIFN) + ribavirin (RBV) (n = 384), SOF + RBV (n = 227), or
SOF + simeprevir (SMV, a second generation protease inhibitor,
PI) ± RBV (n = 320). Thirty percent of the patients had cirrhosis
and 43% were treatment-experienced (TE, including 20% of
patients with history of failure to triple therapy with a PI).
Intention-to-treat analysis showed SVR12 rates of 77% with
SOF + PegIFN/RBV, 50% with SOF + RBV, and 82% with
SOF + SMV ± RBV in G1-infected patients. Patients with cirrhosis
had lower rates of SVR12 when treated with SOF + PegIFN/RBV
(62% in cirrhotics vs. 76% in non-cirrhotics); the impact of cirrho-
sis on SVR12 rate appeared less important in patients receiving
SOF + SMV (76% in cirrhotics vs. 87% in non-cirrhotics).15 vol. 62 j 1196–1203
Table 1. Summary of clinical studies in patients with chronic hepatitis C presented at the AASLD Liver Meeting.
Author (reference) Type of 
study
Population Cirrhosis 
n (%)
Treatment SVR
Dieterich et al. [1] Real-life Chronic hepatitis C (n = 955)
TN and TE
291 (30) SOF + PEG + RBV 12 weeks (G1)
SOF + RBV 12 weeks (G2)
SOF + SMV ± RBV 12 weeks (G1)
77%
84%
82%
Jenssen et al. [2] Real-life Chronic hepatitis C (n = 2063)
TN and TE
999 (49) SOF + PEG + RBV 12 weeks (G1)
SOF + RBV 12 weeks (G2)
SOF + SMV ± RBV 12 weeks (G1)
85%
90%
89%
Bourliére et al. [3] Trial Chronic hepatitis C 
PI failures (n = 154)
154 (100) SOF + LDV ± RBV 12 weeks
SOF + LDV 24 weeks
96%
97%
Wyles et al. [4] Trial SOF failures (n = 51) 15 (29) SOF + LDV + RBV 12 weeks 98%
Nelson et al. [5] Trial Genotype 3, TN and TE (n = 152) 32 (21) SOF + DCV 12 weeks TN 90%
TE 86%
Bourliére et al. [6] Trial Cirrhotics included in phase 2 and 
3 trials with SOF + LDV (n = 513)
513 (100) SOF + LDV ± RBV 12 weeks
SOF + LDV ± RBV 24 weeks
95%
98%
Flamm et al. [7] Trial Decompensated cirrhosis 
Genotype 1 or 4 (n = 108)
108 (100) SOF + LDV + RBV 12 weeks
SOF + LDV + RBV 24 weeks
87%
89%
Reddy et al. [8] Trial Liver transplant recipients (n = 223) 112 (50) SOF + LDV + RBV 12 weeks
SOF + LDV + RBV 24 weeks
92%
94%
Mantry et al. [9] Trial Liver transplant recipients (n = 34) 0 Paritaprevir/r + ombitasvir + 
dasabuvir + RBV 24 weeks
97%
Pungpapong et al. 
[10]
Real-life Liver transplant recipients (n = 109) 28 (26) SOF + SMV ± RBV 12 weeks 91%
Muir et al. [11] Trial Genotype 1, TN and TE  (n = 202) 202 (100) DCV + ASV + BCV 12 weeks
DCV + ASV + BCV + RBV 12 weeks
TN 98%, TE 93%
TN 93%, TE 87%
Poordad et al. [12] Trial Genotype 1, TN and TE   (n = 415) n.a. DCV + ASV + BCV 12 weeks TN 92%, TE 89%
Sulkowski et al. [13] Trial Genotype 1, TN (n = 94)
HIV co-infection  (n = 59)
n.a. GZP + EBV ± RBV 12 weeks 93-98%
87-97%
Lawitz et al. [14] Trial Genotype 1, cirrhotics, TN, null 
responder with or without cirrhosis 
(n = 253)
170 (67) GZP + EBV ± RBV 12 weeks
GZP + EBV ± RBV 18 weeks
90-97%
94-100%
Lawitz et al. [15] Trial Genotype 1, TN (n = 102) 41 (40) GZP + EBV + SOF 4 weeks
GZP + EBV + SOF 6 weeks
GZP + EBV + SOF 8 weeks
39%
80-87%
95%
SOF, sofosbuvir; PEG, pegylated interferon; RBV, Ribavirin; SMV, simeprevir; LDV, ledipasvir; DCV, daclatasvir; GZP, grazoprevir; EBV, elbasvir; TN, treatment naïve; TE,
treatment-experienced; n.a., not available.
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JOURNAL OF HEPATOLOGYImportantly, tolerance to antiviral therapy was good and only
1.9% of the patients discontinued therapy due to adverse events.
The TARGET cohort, with more than 2000 patients enrolled,
reported SVR4 in patients who received antiviral therapy with
SOF + PegIFN/RBV, SOF + RBV, or SOF + SMV ± RBV [2]. Again,
more than 50% of the patients were TE and 18% had failed a pre-
vious course of triple therapy with a PI. Forty-eight percent of the
patients had cirrhosis and 43% of them had previous history of
decompensation. SVR4 rates were 85% and 89% in patients receiv-
ing SOF + PegIFN/RBV and SOF + SMV ± RBV, respectively. In
patients with decompensated cirrhosis the latter combination
achieved SVR4 rates of 75%, but the degree of liver dysfunction
was not reported for these individuals.
While awaiting the ﬁnal results, preliminary data from these
two study cohorts indicate that: 1) the efﬁcacy of SOF + PegIFN/
RBV in previously treated patients is similar to that predicted
by the FDA (around 70%), 2) the combination of SOF + RBV in
patients with G1-infection is suboptimal (SVR rate of 50%), 3)
the combination of SOF + SMV ± RBV achieves high SVR rates,
even in patients with cirrhosis or clinical decompensation, and
4) the use of ribavirin does not seem to signiﬁcantly increaseJournal of Hepatology 2015SVR rates, but in the absence of randomization strong recommen-
dations cannot be given.
Non-responders to a previous therapy with a DAA
Bourliére et al. studied the safety and efﬁcacy of ledipasvir (LDV, a
NS5A inhibitor)/SOF in cirrhotic patients who had failed triple
therapy with a PI [3]. Patients were randomized to receive place-
bo for 12 weeks followed by 12 weeks of LDV/SOF + RBV, or
24 weeks of LDV/SOF without RBV. The mean MELD score was
7 (range 6–16), 26% of the patients had esophageal varices and
17% had a platelet count <100  103/ll, indicating portal hyper-
tension. Despite being a difﬁcult-to-treat population, SVR12 rates
were 96% and 97% in the 12-week regimen with RBV and the 24-
week regimen without RBV, respectively. Treatment was well tol-
erated and only one patient discontinued therapy because of sep-
sis during the placebo period.
The combination of LDV/SOF + RBV was also evaluated in the
re-treatment of G1-infected patients who had failed previous
therapy with a SOF-based regimen, either SOF in combination
PegIFN + RBV (n = 25) or SOF + RBV (n = 21) [4]. SVR12 was 98%vol. 62 j 1196–1203 1197
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Clinical Trial Watch
and only one patient failed therapy due to relapse. Unexpectedly,
this patient had been misclassiﬁed as G1a, but sequencing analy-
sis at the time of relapse found that the patient was G3a.
Overall, these data suggest that, even in patients who have
failed a previous therapy with a DAA, the combination of LDV/
SOF plus RBV is able to achieve high SVR rates. Moreover, it
appears that the addition of RBV is necessary to shorten treat-
ment duration.Genotype 3-infected patients
Due to the lower efﬁcacy of current DAA against G3, patients
infected with this genotype have become a difﬁcult-to-treat
population. The ALLY-3 study [5], was conducted to evaluate
the combination of SOF and daclatasvir (DCV, a NS5A inhibitor)
in G3-infected patients. In this trial, 101 treatment-naïve (TN)
and 51 TE patients were enrolled. Twenty-two patients had cir-
rhosis. SVR12 was 90% and 86% in TN and TE patients, respective-
ly. SVR12 was markedly lower in patients with cirrhosis (96% in
non-cirrhotics vs. 63% in cirrhotics) independently of whether
the patients had received a previous course of therapy or not.
The main limitation of this trial was the lack of a comparison
group with RBV or with longer duration of therapy (16 or
24 weeks).
It has previously been shown that TE patients with cirrhosis
and G3 infection are a very difﬁcult-to-treat population. Indeed,
SVR12 with the combination of SOF + RBV was only 62% in G3
TE patients with cirrhosis [6]. Despite that both SOF and DCV
have antiviral activity against G3, these data suggest that in
patients with advanced liver ﬁbrosis, a longer treatment duration,
the use of RBV or even a third antiviral drug might be needed to
increase efﬁcacy.Compensated and decompensated cirrhosis
Bourliére et al. [7] presented pooled data from patients with cir-
rhosis enrolled in phase 2 and 3 studies evaluating LDV/SOF.
Overall, SVR12 rate was 96%. Virological failures were due to
relapse (n = 18). A 12-week regimen with LDV/SOF without RBV
achieved a slightly lower virological response (SVR12 of 92%)
compared to a 12-week regimen with RBV (SVR12 of 95%) or a
24-week regimen with or without RBV (SVR12 of 100% and
98%, respectively). Patients with a platelet count <75  103/ll,
had lower chances of achieving SVR12 (84%). This combination
was safe and well tolerated in patients with cirrhosis, but
patients receiving RBV had higher rates of adverse events includ-
ing anemia (hemoglobin <10 g/dl).
In decompensated cirrhotic patients, the SOLAR trial [8]
evaluated treatment with LDV/SOF and RBV for 12 or 24 weeks
in patients with G1 or G4 Child-Pugh B (7–9 points) or C (10–
12 points) cirrhosis. The majority of the patients had a baseline
MELD score between 10 and 20 points. SVR12 were 87% and
89% for 12 and 24-week treatment duration with no differences
between Child-Pugh B or C patients. More importantly, antiviral
therapy was associated with an improvement in MELD scores
in most patients (60–79%), only 4 weeks after treatment ﬁnaliza-
tion. Approximately one third of the individuals had serious
adverse events (more frequently in patients receiving longer
treatment duration), but most of them were not considered as
related to antiviral therapy. Tolerance was good and only three1198 Journal of Hepatology 2015patients discontinued therapy due to adverse events (sepsis, peri-
toneal hemorrhage and hepatic encephalopathy).
In summary, LDV/SOF achieves high SVR rates in patients with
compensated and decompensated cirrhosis. A 12-week regimen
with RBV appears to be the most cost/effective strategy. An
important result from the SOLAR study in decompensated
patients was the improvement in liver function. Pending valida-
tion with a longer follow-up and a higher number of patients,
the data supports the indication of antiviral therapy in this
population, even if they are not on a transplant waiting list.
Since patients with Child-Pugh C >12 points were not included,
the question remains as if viral clearance may or not have an
effect in patients with very advanced cirrhosis.
Liver transplant recipients
Reddy et al. [9] presented the data evaluating LDV/SOF + RBV in
patients with hepatitis C recurrence after liver transplantation
(LT). This trial enrolled patients with all stages of ﬁbrosis includ-
ing F0–F3 (mild to moderate ﬁbrosis) and cirrhosis (Child-Pugh A,
B and C). Two hundred and twenty-three patients were random-
ized to receive LDV/SOF + RBV for 12 or 24 weeks. Most of the
patients were male and were infected by G1a. Median time since
transplantation ranged between 2.9 and 8.1 years. As expected,
patients with preserved liver function achieved higher SVR12
rates (97% F0–F3 and 96% in Child-Pugh A patients) as compared
to patients with decompensated cirrhosis (84% in Child-Pugh B
and 64% in Child-Pugh C patients), without differences between
12-weeks or 24-weeks of therapy. The number of patients with
Child-Pugh C cirrhosis enrolled in this trial is still very low and
makes it difﬁcult to draw any conclusions in this subpopulation.
As usual, virological failures in this study were due to relapse
(n = 8). Importantly, and as shown in immunocompetent
patients, liver function improved in most of the individuals
included in the trial (1 to 8 points decrease in MELD score).
Twenty-ﬁve percent of the patients presented serious adverse
events, but most of themwere not considered as related to antivi-
ral therapy. Adverse events were more common in patients with
severe liver dysfunction or longer treatment duration. Mantry
et al. [10] reported the results of the CORAL-I study aimed at
evaluating the safety and the efﬁcacy of paritaprevir/r, ombitas-
vir, dasabuvir and RBV in 34 liver transplant recipients with mild
to moderate hepatitis C recurrence (F0–F2). Median time since
transplantation was 39.5 months. Eighty-ﬁve percent of the
patients were infected by G1a. SVR was achieved in 97% of the
patients. The only patients who failed to respond to therapy
had NS3, NS5A and NS5B resistance-associated variants at the
time of relapse. Medication was well tolerated and only one
patient discontinued therapy due to adverse events. Due to the
presence of drug-drug interactions between ritonavir and
immunosuppressive drugs, tacrolimus and cyclosporine, doses
needed to be adjusted during therapy. Tacrolimus was reduced
to 0.2 mg/72 h to 0.5 mg/week and cyclosporine was reduced to
one ﬁfth of the pre-treatment dose. Despite the adjustment on
immunosuppression there were no episodes of rejection.
Real-life data from the three sites at the Mayo Clinic were
reported by Pungpapong et al. [11]. One hundred and nine
patients with hepatitis C recurrence after LT received antiviral
therapy with SOF and SMV (with or without RBV). The majority
of patients were infected with G1a, 29% had advanced ﬁbrosis
(F3–F4), and 11% had clinical or histological diagnosis ofvol. 62 j 1196–1203
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cholestatic recurrence. SVR12 rate was 91% in 66 patients who
had reached this time-point. Neither the use of RBV, the response
to a previous treatment course of therapy, or the subtype of G1
were signiﬁcantly associated with SVR12. On the contrary,
SVR12 was signiﬁcantly lower in patients with advanced ﬁbrosis
(F3–F4) as compared to patients with mild or moderate ﬁbrosis
(F0–F2, p = 0.03). Adverse events were mostly mild and unrelated
to the study medication. However, one patient developed a drug-
induced lung injury (conﬁrmed by lung biopsy) and died of mul-
ti-organ failure.
New antiviral combinations
All-oral combination with asunaprevir (a NS3 inhibitor), DCV,
and beclabuvir (a non-nucleotide NS5B inhibitor) was evaluated
in G1-infected patients with [12] and without cirrhosis (n = 202
and n = 415, respectively) [13]. In patients without cirrhosis this
combination obtained SVR12 rates of 92% and 89% in TN and TE
patients, respectively. Thirty-four patients experienced viro-
logical failure, 13 were on-treatment failures, and the remaining
21 were relapses. Resistance-associated variants in NS3, NS5A
and/or NS5B were commonly observed in G1a patients.
Interestingly, G1b patients who failed to respond to therapy
(n = 2) were subsequently classiﬁed as non-G1. In patients with
cirrhosis, SVR12 was 93% and 98% in TN patients with and with-
out RBV, respectively. The values for TE patients were 97% and
93%, with and without RBV. This combination was safe and well
tolerated.
The ﬁnal results of the C-WORHTY trial conducted in 471
patients with G1 chronic hepatitis C were presented [14,15]. In
this phase 2 trial the combination of grazoprevir (MK-5172, a pro-
tease inhibitor) + elbasvir (MK-8742, a NS5A inhibitor) ± RBV was
evaluated in 4 groups of patients: 94 TN non-cirrhotic
patients, treated for 8 (only G1a) or 12 weeks; 59 HIV co-infected,
non-cirrhotic patients, treated for 12 weeks; 123 TN, cirrhotic
patients treated for 12 or 18 weeks; and 130 previous null
responders to antiviral therapy with PegIFN/RBV, with or without
cirrhosis, treated for 12 or 18 weeks. The combination of grazo-
previr and elbasvir was highly effective in all treatment groups:
93%–98% in TN non-cirrhotic patients with 12 weeks of therapy,
87%–97% in HIV co-infected patients without cirrhosis, 90%–97%
in TN cirrhotic patients, and 91%–100% in previous null respon-
ders with or without cirrhosis. The use of RBV or longer treatment
duration did not have an impact on the chances of achieving
SVR12. In G1a-infected patients receiving only 8 weeks of therapy
with RBV, SVR12 was only 80%, indicating the need for longer
treatment duration in these patients. Antiviral therapy with these
two compounds was safe and well tolerated. Serious adverse
events rate was 3% and only 3 patients discontinued therapy.
An interesting trial studied the possibility of ultra-short treat-
ment durations with the combination of three highly potent
DAAs [16]. Sixty-one TN, non-cirrhotic patients were randomized
to receive grazoprevir + elbasvir + SOF for 4 or 6 weeks; and 41
TN patients with cirrhosis, were randomized to receive 6 or
8 weeks of the same combination. In non-cirrhotic patients,
SVR4 rates were 38.7% and 86.7% for 4 and 6 weeks of therapy,
respectively. In patients with cirrhosis SVR4 rates were 80% and
94.7% for 6 and 8 weeks of treatment, respectively. Virological
failures were due to relapse, which were more frequently
observed in G1a patients. At the time of the relapse 10 patients
had NS5A RAVs (5 were also present at baseline). One patientJournal of Hepatology 2015had both, NS3 and NS5A RAVs. These data suggest that treatment
regimens therapy in selected patients receiving a combination of
highly potent drugs could be reduced in length, however going
below 4–6 weeks has proven unsuccessful even in easy-to-treat
individuals.
Hepatitis B
Despite being the major endpoint of antiviral therapy in patients
with chronic hepatitis B, HBsAg loss is achieved in a minority of
patients receiving antiviral treatment with nucleotide analogs
or PegIFN. In this study, Marcellin et al. [17] aimed to investigate
the rate of HBsAg loss at week 72 with a ﬁnite combination of
tenofovir (TDF) + PegIFN. In this trial 740 patients were random-
ized to receive TDF + PegIFN for 48 weeks (Group 1),
TDF + PegIFN for 16 weeks followed by monotherapy with TDF
until completing 48 weeks (Group 2), indeﬁnite treatment with
TDF monotherapy (Group 3), or PegIFN for 48 weeks (Group 4).
At weeks 72, HBsAg loss rate was signiﬁcantly higher in Group
1 (9%) as compared to the other treatment groups (2.8%, 2%,
and 0% for Groups 2, 3, and 4, respectively). It is important to
note, though, that seven patients presented seroreversion (4 in
Group 1 and 4 in Group 2). These data support the combination
of TDF and PegIFN, but further studies are needed to conﬁrm the-
se results.
In summary, data presented showed an outstanding advance
in the treatment of hepatitis C, especially in difﬁcult-to-treat
populations who are at high need of viral eradication: patients
with cirrhosis and clinical decompensations, liver transplant reci-
pients, patients with previous failure to a ﬁrst generation pro-
tease inhibitor. However, the optimal duration of therapy and
the use of RBV are still a matter of debate.Complications of cirrhosis
Type I hepatorenal syndrome (HRS) is an uncommon but omi-
nous complication in cirrhosis. The current standard therapy is
based on the combination of vasoconstrictors plus albumin
[18,19]. Terlipressin has been the vasoconstrictor most thorough-
ly assessed so far. In fact a recent meta-analysis shows that it is
superior to placebo in the reversal of type I HRS [20]. However,
terlipressin is still not approved by the FDA for this indication.
Boyer et al. presented the initial results of a phase 3 multicenter,
randomized trial comparing terlipressin + albumin vs. place-
bo + albumin in the treatment of HRS (the REVERSE study,
[21]). The primary endpoint was ‘‘conﬁrmed HRS reversal’’,
deﬁned as two serum creatinine values 61.5 mg/dl at least 48 h
apart, on treatment. One hundred and ninety-six patients were
enrolled. There were no signiﬁcant differences in the rate of con-
ﬁrmed responses between the two groups (20% in terlipressin vs.
13% in placebo), or on 90-day survival. Terlipressin, however,
induced a signiﬁcantly greater decrease in creatinine than place-
bo. The same authors presented [22] the pooled data from this
study and a previous one with similar design [23], showing a sig-
niﬁcant improvement in the rate of conﬁrmed HRS reversal.
Survival was signiﬁcantly higher and the need for renal replace-
ment therapy lower in patients achieving reversal.
Vasoconstrictors are also the mainstay of therapy in septic
shock, but the optimal vasoconstrictor for patients with cirrhosis
and septic shock remains unknown [24]. Choudhury et al. [25]vol. 62 j 1196–1203 1199
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randomized 78 patients with cirrhosis and septic shock to con-
tinuous infusion of terlipressin or noradrenaline (in addition to
standard medical care). The study was designed as a non-
inferiority trial. The primary endpoint was maintenance of a
MAP >65 mmHg at 6 h after the onset of infusion. The main cause
of septic shock was spontaneous bacterial peritonitis (SBP).
Terlipressin was not inferior to noradrenaline in achieving the
primary endpoint. There were no differences in the overall
survival.
Infections due to multiresistant bacteria are an increasing
problem in cirrhosis, especially in those with nosocomial infec-
tions [26–28]. This issue was addressed in two randomized clin-
ical trials evaluating the optimal empirical antibiotic therapy in
patients with SBP at risk of infection by resistant bacteria.
Piano et al. [29] conducted a randomized trial in 32 patients with
cirrhosis comparing meropenem + daptomycin vs. ceftazidime in
the empirical treatment of nosocomial SBP. The primary outcome
was resolution of SBP at 7 days, and was achieved in 87% of the
patients with meropenem + daptomycin and 25% with cef-
tazidime. Along the same lines, a second randomized trial pre-
sented by Jindal et al. [30], compared imipenem vs. cefepime in
175 patients with difﬁcult-to-treat SBP (deﬁned as nosocomial
SBP, lack of initial response at 48 h to initial therapy or recurrent
SBP). Resolution of SBP was achieved in 66% and 61% of the
patients with imipenem and cefepime, respectively. The results
of these two trials suggest that the most effective empirical treat-
ment for patients with SBP at high risk of having resistant bacte-
ria is likely the combination of a carbapenemwith an agent active
against resistant Gram positive cocci, though this might need
adjustments to the local patterns of resistance.
Two randomized trials assessed the potential of probiotics for
the management of hepatic encephalopathy (HE). Dhiman et al.
[31] randomized 130 patients with cirrhosis who recovered from
an episode of HE to receive VSL#3 or placebo (6 months treat-
ment) for the prevention of HE recurrence. Probiotics achieved
a non-signiﬁcant reduction in the rate of recurrent HE as
compared with placebo, but signiﬁcantly decreased the rate of
hospitalization, improved liver function and decreased serum
pro-inﬂammatory markers in serum (TNFa, IL-1B, and IL-6). In
another randomized trial Vlachogiannakos et al. [32] randomized
72 patients with cirrhosis diagnosed of minimal hepatic
encephalopathy (MHE) to receive probiotics (Lactobacillus plan-
tarum 299v) or placebo for 3 months. MHE was diagnosed by
an abnormal NCT or abnormal brainstem auditory evoked poten-
tials. Administration of the probiotic achieved reversal of MHE in
a signiﬁcantly greater proportion than placebo (57% vs. 7%). The
rate of progression to overt HE was 0% and 17% respectively.
These randomized trials suggest that the manipulation of the
microbioma in patients with cirrhosis may have a role in the
management of HE, though the effect of probiotics seems mild.
A decrease in portal pressure (evaluated by the hepatic
venous pressure gradient or HVPG) is an excellent surrogate end-
point for improved outcomes in cirrhosis [33,34] and it has been
used as a gold standard for proof of concept studies for new inter-
ventions. Two studies assessed the effects of diet and exercise on
portal pressure in cirrhosis. Berzigotti et al. [35] evaluated the
effects on portal pressure during a 16 week program of hypocalo-
ric diet and supervised exercise in 50 obese cirrhotic patients
(72% Child-Pugh A). The intervention reduced body weight and
HVPG by a median of 5% and 11% respectively. Weight reduction
was associated with the decrease in portal pressure, and 42%1200 Journal of Hepatology 2015achieved a HVPG decrease P10%, showing the potential clinical
impact of the intervention. The beneﬁcial effects of diet and exer-
cise might not be limited to obese patients [36]. In a small ran-
domized control trial (n = 23) Macias-Rodriguez et al. [37]
compared the effects on portal pressure of a 14-weeks physical
exercise program combined with nutritional intervention vs.
nutritional intervention alone in non-obese patients with cirrho-
sis, mostly Child-Pugh A. The exercise program was safe and
associated with a signiﬁcant reduction in HVPG as compared to
the nutritional intervention group.
In summary, data from AASLD: 1) conﬁrmed the beneﬁcial
effects of terlipressin in patients with cirrhosis and septic shock,
2) proved that antibiotic therapy for cirrhotic patients with
nosocomial infection should include a carbapenem plus and
anti-cocci agent, 3) evidenced that microbioma may play an
important role in the development of HE, and 4) demonstrated
that exercise and diet have a beneﬁcial effect on portal pressure.Non-alcoholic fatty liver disease and alcoholic liver disease
Non-alcoholic fatty liver disease (NAFLD) is currently one of the
most common liver disorders both in the US and Europe
[38,39]. It may progress to non-alcoholic steatohepatitis
(NASH), which markedly increases the risk of cirrhosis and
hepatocellular carcinoma (HCC) [40].
Novel approaches in diagnosis and treatment in NAFLD and non-
alcoholic steatohepatitis (NASH)
Liver biopsy is often performed to conﬁrm the diagnosis of
NAFLD and diagnose NASH in high risk groups (e.g., patients with
obesity, type-2 diabetes mellitus, dyslipidemia and metabolic
syndrome). However, little is known about the long-term prog-
nostic information that can be obtained from grading and staging
the disease. In order to ﬁll this gap, at this AASLD Liver Meeting,
Angulo et al. [41] presented the results of the PRELIHIN study,
aimed to determine the long-term prognostic relevance of liver
histological features in patients with NAFLD. In this prospective
multicenter study, the authors analyzed the clinical value of his-
tological features of 619 patients with conﬁrmed NALFD, with a
median follow-up of 12.6 years. They showed that age, diabetes
and any stage of ﬁbrosis at liver biopsy were independently asso-
ciated with the primary outcome (e.g., death/LT). On the contrary,
statin use was associated with a risk reduction (HR 0.32;
p = 0.005). They also showed that an advanced ﬁbrosis stage (F3
or F4 vs. F0; HR 14.2, p <0.001 and 51.5, p <0.001, respectively)
was the only histological variable associated with liver-related
events during follow-up. The authors concluded that ﬁbrosis
stage, but no other histological features or presence of NASH, is
associated with important clinical outcomes on long-term fol-
low-up of patients with NAFLD.
Given its impact on hard clinical outcomes, targeting ﬁbrosis
among patients with NAFLD/NASH is an important issue. One tri-
al and one prospective cohort study including positive data of
NAFLD/NASH and ﬁbrosis, were presented in parallel sessions.
In the ﬁrst study, Harrison et al. [42] presented their results on
safety and efﬁcacy of GR-MD-02 (a galectin-3 inhibitor that has
beneﬁcial therapeutic effects in rodent models of NASH and tox-
in-induced cirrhosis) in patients with NASH and F3 ﬁbrosis stage.
In this early phase 1 study, 8 patients were randomized (3:1) tovol. 62 j 1196–1203
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receive 4 doses of either placebo or GR-MD-02 by intravenous
infusion on days 0, 28, 35, and 42. Serum biomarkers of ﬁbrosis
(e.g., FibroTest and Enhanced Liver Fibrosis (ELF) score) were
assessed at day 1 and day 56. The authors report a good safety
proﬁle of the experimental drug, with no severe adverse events in
both groups. A signiﬁcant reduction of FibroTest score (by a
marked reduction in alpha-2-macroglobulin) was achieved in
patients treated with GR-MD-02 vs. placebo (27% vs. 3.5%;
p = 0.04); however, no signiﬁcant changes were found in ELF
score. Finally, the authors inform that a clinical trial using a dose
of 4 mg/kg of GR-MD-02, which will be followed by an 8 mg/kg
dose cohort, is ongoing.
In the second study, Lassailly et al. [43] presented the results
from one of the largest prospective cohort studies on the effects
of bariatric surgery in morbid obese patients with histologically
conﬁrmed NASH. The study recruited 109 patients (89 with
paired liver biopsies at 1 year of follow-up) over a time frame
of 20 years. Anthropometric, biochemical and histological para-
meters were compared before and after one year from the surgi-
cal procedure. A signiﬁcant improvement in anthropometric and
biochemical parameters (e.g., BMI, insulin resistance index, ALT,
GGT and HbA1c) were achieved. Importantly, NASH disappeared
in 85% of cases and all histological features improved: steatosis
(58.5 ± 22 to 17.2 ± 20%), ballooning (1.4 ± 0.5 to 0.3 ± 0.6),
inﬂammation (1.3 ± 0.5 to 0.5 ± 0.6), NASH grading (1.5 ± 0.7 to
0.2 ± 0.6), NAS (4.9 ± 1 to 1.6 ± 1.5) and ﬁbrosis (1.2 ± 1.1 to
0.9 ± 1.1) (for all: p <0.001). The authors conclude that bariatric
surgery might be used as an effective treatment after failure of
lifestyle intervention in morbid obese patients with NASH.
Advances in the treatment of alcoholic liver disease: focus on severe
alcoholic hepatitis
Alcoholic hepatitis (AH) is a type of acute-on-chronic liver failure
and the most severe form of alcoholic liver disease [44]. In its sev-
ere form, AH carries a poor short-term prognosis. Although cur-
rent guidelines recommend an adequate enteral nutrition
support, in these patients the recommended protein-caloric
intake is often difﬁcult to achieve and effects of this maneuver
compared with corticosteroids alone (the ﬁrst line of therapy)
has not showed any differences on short-term mortality [45].
However, the impact of enteral nutrition as an adjunctive therapy
with corticosteroids is unknown. In this AASLD Liver Meeting
Moreno et al. [46] presented the results of a multicenter random-
ized controlled trial addressing this question. Two groups were
included: 1) intensive enteral nutrition plus methylprednisolone
(intensive group) and 2) conventional nutrition plus methylpred-
nisolone (control group). In the intensive group, enteral nutrition
was given using a feeding tube for 14 days and patients received
Fresubin HP Energy (1.5 kcal/ml, 7.5 g prot/100 ml): 1 L per day
if body weight (BW) <60 kg, 1.5 L if BW between 60 and 90 kg, 2 L
if BW >90 kg. The authors showed a signiﬁcant improvement in
6-month survival (69.8 vs. 46.8%; p = 0.015, intensive vs. control
group, respectively) when analyzing patients who received at
least 80% of the planned kcal intake, deﬁned by the protocol
(per-protocol analysis). Importantly, on intention-to-treat analy-
sis, the 6-month survival was not statistically different between
the two groups: 55.9 vs. 47.0% (p = 0.316). Consequently, this trial
fails to demonstrate the beneﬁcial effects of intensive nutrition in
severe AH. However, adequate nutritional support was associated
with a better prognosis at 6-months.Journal of Hepatology 2015In the clinical plenary session, Thursz et al. [47], presented the
results of the STOPAH trial, a multicenter, double-blind, factorial
(2  2) design which randomized 1093 patients with severe AH
(discriminant function P32) in 63 centers from the UK, to one
of four groups of treatment: Group A: placebo/placebo, Group
B: placebo/prednisolone, Group C: pentoxifylline/placebo and
Group D: pentoxifylline/prednisolone. The trial aimed to provide
sufﬁcient power to determine whether either of the two inter-
ventions was effective in a non-biopsy proven cohort of AH.
The primary endpoint (PE) was mortality at 28 days, with sec-
ondary endpoints (SE) being mortality at 90 days and 1 year.
For pentoxifylline the odds ratio (OR) for PE was 1.07 (95% CI
0.77–1.49; p = 0.68) and for prednisolone the OR for PE was
0.72 (95% CI 0.52–1.01; p = 0.056). Importantly, when adjusting
for baseline severity and prognostic factors (e.g., age, INR, urea,
WBC, creatinine and HE) the OR in the prednisone treated group
was 0.61 (95% CI 0.41–0.90; p = 0.01). No signiﬁcant differences
were found between treatment groups for SE. The authors con-
cluded that prednisolone reduces the risk for 28-day mortality
in 39% without impact beyond this time. Pentoxifylline treat-
ment had no impact on PE or SE.
This meeting brought some important information regarding
NAFLD and alcoholic liver disease: 1) advanced ﬁbrosis at base-
line biopsy is the major predictor of disease progression, death,
or LT, 2) bariatric surgery has a beneﬁcial impact on liver disease
in patients with NAFLD, 3) adequate nutritional support improves
outcome in patients with AH, and 4) pentoxifylline has no impact
on survival in patients with AH.Hepatocellular carcinoma: no big news but continuous
improvement
The risk of developing HCC depends on the etiology of the liver
disease. Among those, chronic hepatitis B virus infection is the
world’s leading cause of HCC [48]. It is crucial to identify patients
at risk of HCC development to target surveillance population.
Currently, there are several models but they require HBV DNA
quantiﬁcation, which may be a costly test in some areas of the
world. Poh et al. [49] developed a score based on 673 chronic
hepatitis B patients followed in Singapore for 10 years. Forty-
three patients developed an HCC. The score is based on gender,
age, cirrhosis and AFP level. The high risk group was deﬁned as
a score P4.5. This score was validated on three independent
cohorts totalizing 2586 patients. Nevertheless, the score took
only into account baseline data, there was no time (survival) ana-
lysis and no treatment response was assessed.
Diabetes is another well recognized risk factor for HCC based
on cohort or case control studies [50]. King et al. [51] reported an
analysis coming from two prospective cohorts including lifestyle
assessment. Over 30 years of follow-up, they identiﬁed 163 cases
of HCC over 3,891,069 person/years. Diabetics had a higher risk of
HCC (3.52, 95% CI: 2.44–5.08) compared to non-diabetics after
adjustment for age, sex, BMI, aspirin use, smoking status and
alcohol intake. The risk appeared to be independent of the sex,
the duration of the diabetes, the BMI and the physical activity.
Diagnosis of HCC at an early stage is crucial for a successful
treatment. For this purpose, ultrasound surveillance every
6 months is recommended by the international guidelines.
Goldberg et al. [52] analyzed the database from a US commercial
health insurance. Among 8916 cirrhotic patients followed during
a median of 22.9 months, only 8.8% had a complete surveillance,vol. 62 j 1196–1203 1201
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in 55.4% it was incomplete (ultrasound assessments missing) and
35.8% had no surveillance at all. Factors associated with incom-
plete surveillance were non-GI provider, non-PPO (Preferred
Provider Organization) insurance, and elderly. Factors associated
with ‘‘good’’ surveillance were a history of liver decompensation,
a metabolic syndrome and a diagnosis of hepatitis B or C. The
study stresses the lack of a correct information among HCC
surveillance among physicians and the beneﬁts of a specialized
care (gastroenterologists and hepatologists) in cirrhotic patients.
When HCC is diagnosed at an early stage, radiofrequency abla-
tion (RFA) provides very good results. New techniques for percu-
taneous tumor ablation have been developed during the last
decade. Wang et al. [53] reported the results of a randomized
control trial comparing RFA to cryoablation in 360 patients with
1 or 2 tumors, 64 cm. Local tumor recurrence was signiﬁcantly
more frequent after RFA compared to cryoablation at 1, 2, and
3 years but signiﬁcantly more patients with two tumors were
included in RFA group. There was no difference in terms of safety,
overall survival, and tumor-free survival.
Liver resection (LR) is another treatment option for early HCC.
Antiplatelet therapy has been recently shown to prevent hepato-
carcinogenesis in animal models of HBV-induced HCC. Su et al.
[54] presented a study that included 9461 patients with
HBV-related HCC in Taiwan. Patients underwent LR between
1997 and 2011. After matching by sex, age and propensity score,
2210 patients were analyzed. Recurrence-free survival and over-
all survival were signiﬁcantly better in patients who were under
antiplatelet treatment, but the incidence of tumor recurrence was
not reported. Moreover, statins were used more frequently in the
antiplatelet group (p = 0.054). Overall, based on the data present-
ed at the meeting, it is difﬁcult to understand the real effect of
antiplatelet therapy on prevention of tumor recurrence.
Test of time is one of the best tools for patient selection. In the
LT setting, the waiting time is a ‘‘double-edged sword’’ for HCC
patients, with the drop-out risk in one hand and a better candi-
date selection in the other. Mehta et al. [55] reported a series of
881 patients listed for LT for HCC in three centers with different
waiting times. The 5-year post-LT patient survival was sig-
niﬁcantly better for patients with a waiting time P6 months
(p = 0.02). However, a waiting time <6 months was not associated
with a higher tumor recurrence in a multivariate analysis (mak-
ing it difﬁcult to interpret the waiting time effect). In the same
area the crucial question of tumor downstaging feasibility is still
under debate. A recent international consensus conference con-
cluded that further evidences are needed. Mehta et al. [56]
reported a multicenter experience on 187 patients fulﬁlling the
downstaging criteria previously described, with at least 3 months
of observation. The drop-out rate was 36%. The 5-year post-LT
survival was 80% and the 5-year recurrence-free probability
was 87% in transplant patients. For the whole study population
(transplanted and not) a 5-year intent-to-treat survival of 56%
was reached. Factors predicting tumor recurrence were pre-treat-
ment AFP >500 and microvascular invasion. This study strongly
supports that downstaging patients using stringent criteria is a
safe procedure to allow some of them to access to LT.
No clinical trials on advanced stage HCC were released.
The AASLD Liver Meeting showed us that: 1) diabetes, age
and male gender are, as previously demonstrated, risk factors
for the development of HCC, 2) percutaneous treatment with
cryoablation is associated with lower rates of tumor recurrence
but has no impact on tumor-free survival rate, 3) the beneﬁcial1202 Journal of Hepatology 2015effect of antiplatelet therapy on survival and tumor-free survival
after LR for HCC needs further studies and 4) downstaging seems
to be safe allowing more patients to get access to LT.
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